AMAG Pharmaceuticals continues to support healthcare providers and patient advocacy organizations invested in the fight against prematurity. AMAG Pharmaceuticals is dedicated to playing an active role in helping reduce the preterm birth rate through collaboration with healthcare providers to advance patient care, ongoing research and development, and partnering in community educational initiatives.
The Makena Care Connection® is a dedicated customer support program for patients and their healthcare providers that helps facilitate the prescription process according to each patient's unique maternity benefits.
The My Adherence Program is designed to encourage patient compliance with the weekly injection schedule for Makena. The free program includes outreach support and education by maternal health nursing specialists throughout the duration of the patient's pregnancy. Outreach calls focus on:
Step-by-step instructional yoga video of restorative poses for expecting mothers.
Stephanie Kinney, a certified yoga instructor, demonstrates a 20 minute sequence of restorative poses for expecting mothers. She shows how you can engage in a restorative practice of yoga with everyday household items. Talk to your healthcare provider before starting any exercise program.
Miracle Babies provides support and financial assistance to families with critically ill newborns in the Neonatal Intensive Care Unit; and to enhance the well-being of women, children and their families through education, prevention and medical care. To learn more, visit www.miraclebabies.org.
AMAG Pharmaceuticals is a proud corporate partner of Sidelines. Our partnership helps advance the mission of Sidelines of providing support for women and their families experiencing complicated pregnancies and premature births. To learn more about how Sidelines can support your high-risk patients, please visit www.sidelines.org.
Learn about preterm birth with The Balancing Act
Join the host of The Balancing Act–a Lifetime Television morning show delivering helpful solutions for today's busy on-the-go modern women–as she speaks with real moms of preemies and a Maternal-Fetal Medicine Specialty about preterm birth.
Makena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.
Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.
Please see full prescribing information for Makena.